|Articles|September 25, 2016
Tufts CSDD Releases Findings from Diabetes Study
September 26, 2016
Advertisement
According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.
Read the full release
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
2
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
3
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
